Clinicopathological features of lymph node metastasis rules of non-small cell lung cancer

doi:10.3877/cma.j.issn.2095-655X.2016.04.008

Abstract

Abstract:

Objective

To explore the clinicopathological features of the lymph node metastasis rules of non-small cell lung cancer ( NSCLC).

Methods

Eighty cases of lung cancer patients underwent surgical resection and lymph node dissection of extensive hilar, leaves room and mediastinum.A total of 602 groups of lymph nodes were removed.The lymph node metastasis rules of NSCLC and their relations with clinicopathological features were analyzed.T stage, pathologic type, differentiation degree and the primary site were statistically analyzed.

Results

Among the 602 groups of lymph nodes, the metastatic rates of N1 and N2 ( including N1+ N2) nodes were 18.8% and 30.4%.There were significant differences in lymph node metastasis among primary lung cancer T stage T1, T2, T3 and T4(χ²=50.702, P=0.000). Saltatory metastatic nodes accounted for 31.8% of N2 metastatic nodes.

Conclusions

Lymph node metastasis is related with T staging of NSCLC, with more jumping mediastinal lymph node metastasis.There are no significant relationships between tumor location, pathological types or type of lymph node metastasis.

Key words: Carcinoma, non-small-cell lung, Lymph node excision, Lymphadenectomy, Disease features

Daosheng Li, Yuanyuan Ban, Hong Ye, Gang Hou. Clinicopathological features of lymph node metastasis rules of non-small cell lung cancer[J]. Chinese Journal of Diagnostics(Electronic Edition), 2016, 04(04): 249-252.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2016.04.008

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2016/V04/I04/249

Figures/Tables 5

References 15

[1]	陈武飞,滑炎卿. 早期肺癌低剂量CT筛查的研究进展[J/CD]. 中华诊断学电子杂志, 2015, 3(3): 192-194.
[2]	曹文荣,闫文修,王雪利. 非小细胞肺癌组织中VEGF和Bax的表达及意义[J]. 重庆医学, 2016, 45(3): 307-309.
[3]	Siegel R,Ma JM,Zou ZH, et al.Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1): 9-29.
[4]	Rami-Porta R,Bolejack V,Goldstraw P. The new tumor, node, and metastasis staging system[J]. Semin Respir Crit Care Med, 2011, 32(1): 44-51.
[5]	Naruke T,Suemasu K,Ishikawa S. Lymph node mapping and cura bility at various levels of metastasis in resected lung cancer[J]. J Thorac Cardiovasc Surg, 1978, 76(6): 832-839.
[6]	Ramnath N,Dilling TJ,Harris LJ, et al.Treatment of stage III non-small cell lung cancer：Diagnosis and management of lung cancer, 3rd ed：American college of chest physicians evidence-based clinical practice guidelines[J]. Chest, 2013, 143(5 Suppl): e314S-e340S.
[7]	Zhong W,Yang X,Bai J, et al.Complete mediastinal lynphadenectomy：the core component of the multidisciplinary therapy in resectable non-small cell lung cancer[J]. Eur J Cardiothorac Surg, 2008, 34(1): 187-195.
[8]	王可兵,杨锦雷,陈建华, 等.112例非小细胞肺癌淋巴结转移规律分析[J]. 临床肺科杂志, 2015, 20(2): 234-236.
[9]	蒋华勇,刘克强,谭健, 等. 肺腺癌与鳞癌胸内淋巴结转移及其与临床病理参数的相关性分析[J]. 临床军医杂志, 2014, 42(10): 1024-1026.
[10]	Whitson BA,D'Cunha J,Andrade RS, et al.Thoracoscopic versus thoracotomy approaches to lobectomy：differential impairment of cellular immunity[J]. Ann Thorac surg, 2008, 86(6): 1735-1744.
[11]	朱军,翁鸢,蔡铭, 等. 非小细胞肺癌伴纵隔淋巴结肿大胸腔镜下纵隔淋巴结清扫的探讨[J]. 临床肺科杂志, 2014, 18(12): 2146-2148.
[12]	Wu YI,Huang ZF,Wang SY, et al.A randomized trial of systemic nodal dissection in resectable non-small cell lung cancer[J]. Lung Cancer, 2002, 36(1): 1-6.
[13]	王文才,火旭东,王进, 等. 胸腔镜与传统开胸手术对早期非小细胞肺癌治疗的比较研究[J]. 临床肺科杂志, 2014, 18(11): 2062-2064.
[14]	张轶,朱余明,陈晓峰, 等.518例早期肺癌的电视胸腔镜肺叶切除术[J]. 中华胸心血管外科杂志, 2012, 28(5): 274-277.
[15]	Watanabe S,Oda M,Tsunezuka Y, et al.Peripheral small-sized (2cm or less) non-small cell lung cancer with mediastinal lymph node metastasis；clinicopathologic features and patterns of nodal spread[J]. Eur J Cardiothorac Surg, 2002, 22(6): 995-999.

T分期	分期标准
T1	肿瘤最大径≤3 cm，由肺或肺层胸膜包绕，支气管镜下没有侵袭比叶支气管更近端的部位，即不在主支气管内
T2	肿瘤具有以下任何的大小和范围：最大径>3 cm；累及主支气管，距离隆突2 cm或更近；侵及脏层胸膜；导致的肺不张或阻塞性肺炎累及致肺门区但未累及全肺
T3	任何大小的肿瘤直接侵犯以下任何部位：胸壁，横隔，纵隔胸膜，心包壁；或肿瘤位于主支气管内，距离隆突小于2 cm但未累及隆突；或导致全肺的肺不张或阻塞性肺气肿
T4	任何大小的肿瘤直接侵犯以下任何部位：纵隔，心脏，大血管，气管，食管，椎体，隆突；同一肺叶存在其他不相连的肿瘤结节；肿瘤伴有恶性胸膜渗出液

T分期	分期标准
T1	肿瘤最大径≤3 cm，由肺或肺层胸膜包绕，支气管镜下没有侵袭比叶支气管更近端的部位，即不在主支气管内
T2	肿瘤具有以下任何的大小和范围：最大径>3 cm；累及主支气管，距离隆突2 cm或更近；侵及脏层胸膜；导致的肺不张或阻塞性肺炎累及致肺门区但未累及全肺
T3	任何大小的肿瘤直接侵犯以下任何部位：胸壁，横隔，纵隔胸膜，心包壁；或肿瘤位于主支气管内，距离隆突小于2 cm但未累及隆突；或导致全肺的肺不张或阻塞性肺气肿
T4	任何大小的肿瘤直接侵犯以下任何部位：纵隔，心脏，大血管，气管，食管，椎体，隆突；同一肺叶存在其他不相连的肿瘤结节；肿瘤伴有恶性胸膜渗出液

病理类型	例数	N0期	N1期	N1＋N2期	N2期	χ²值	P值
鳞状细胞癌	47	26	9	12	4	0.11	0.737
腺癌	33	17	6	10	3	0.11	0.737

病理类型	例数	N0期	N1期	N1＋N2期	N2期	χ²值	P值
鳞状细胞癌	47	26	9	12	4	0.11	0.737
腺癌	33	17	6	10	3	0.11	0.737

分化程度	例数	N0期	N1期	N1＋N2期	N2期	χ²值	P值
高分化	15	7	3	5	2	0.44	0.803
中分化	37	21	8	8	2
低分化	28	15	4	9	3

Please choose a citation manager

Content to export